Jordan News UpdatesA Royal Decree has been issued restructuring the Crown Prince Foundation’s (CPF) board of trustees, under the chairmanship of Ghassan Nuqul.
Members of the newly-appointed board are: Saad Muasher, Walid Tarawneh, Muna Sikhtian, Omar Hamarneh, Thaer Najdawi, Fadia Samara, Ahmad Rafi’ and Zaid Al Farkh.
The appointments were according to the provisions of Article (5) Paragraph (a) of the Crown Prince Foundation Law of 2015.
Source: Jordan News Agency
Hikma Pharmaceuticals, the multinational pharmaceutical company, announced Tuesday it signed new exclusive licensing agreements with Celltrion Healthcare Co., Ltd for CT-P43 (ustekinumab), a monoclonal antibody that is a proposed biosimilar to Janssen’s Stelara.
Under the terms of the agreement, Hikma will have exclusive rights to commercialize CT-P43 in all of its MENA (Middle East and North Africa) markets and Celltrion Healthcare will develop, manufacture and supply CT-P43 to Hikma, Hikma said in a statement.
CT-P43 is an important drug used in the treatment of autoimmune disesases such as Crohn’s disease and ulcerative colitis, and the agreement will help equip doctors and patients with more treatment options across the region, it said.
This agreement also builds on Celltrion Healthcare and Hikma’s existing partnership in MENA, adding another immunology biosimilar to Hikma’s portfolio, a key focus of its strategy, the statement pointed out.
“We are excited to add CT-P43 to our portfolio, strengthening our offering of biosimilar and innovative biologic products,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA.
“CT-P43 is the sixth immunology biologic we add to our portfolio in MENA. This new addition enables us to increase patients’ access to important specialty products, helping them in their treatment journey for these difficult diseases,” he said.
Source: Jordan News Agency